Holen Sie sich die Stockscreener-App
118.09
3.89%
3.7499
Inhibrx Biosciences Inc Aktie (INBX) Neueste Nachrichten
Inhibrx stock, Eikon stock rise on insider buying (INBX:NASDAQ) - Seeking Alpha
H.C. Wainwright reiterates Inhibrx Biosciences stock rating at buy - Investing.com
H.C. Wainwright reiterates Inhibrx Biosciences stock rating at buy By Investing.com - Investing.com Canada
Inhibrx: Market's Lukewarm Response To Yesterday's HNSCC Data Hard To Fathom (NASDAQ:INBX) - Seeking Alpha
Inhibrx director Jon Kayyem buys $567,580 in company stock By Investing.com - Investing.com Australia
Inhibrx (INBX) investor files notice to sell 500 shares - Stock Titan
Family trust tied to Inhibrx (INBX) director buys more stock in open market - Stock Titan
Inhibrx Biosciences reports strong Phase 2 INBRX-106 data - TipRanks
Inhibrx (INBX) director buys 2,500 shares via family trust - Stock Titan
Inhibrx Biosciences (INBX) chief boosts stake with 25,000-share buy - Stock Titan
80% response in HPV+ head and neck cancer lifts Inhibrx (INBX) trial plans - Stock Titan
Why Inhibrx Biosciences (INBX) Stock Is Down Today - quiverquant.com
Inhibrx Biosciences Plans Head and Neck Cancer Trial Expansion Following High Response Rates - TradingView
Inhibrx reports INBRX-106 Phase 2 cancer trial results - grafa.com
Inhibrx cancer therapy outperforms Merck’s Keytruda in mid-stage trial - Seeking Alpha
Inhibrx Biosciences Announces Primary Endpoint Results from Phase 2 HexAgon Study Of INBRX-106 In Combination With Pembrolizumab In HNSCC - marketscreener.com
Phase 2 primary endpoint results for INBRX106 revealed by Inhibrx Biosciences in HNSCC trial - Traders Union
Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study - PR Newswire
(INBX) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
Cancer drug study results are due Sept. 8 from Inhibrx - Stock Titan
INBX Q2 2026 Earnings: Loss of $2.34 per Share Beats Consensus, Stock FlatEarnings Quality Analysis - vinanet.vn
Inhibrx Biosciences (INBX) Holds at $124.97 as Range-Bound Trading ContinuesRVOL Breakout - vinanet.vn
Inhibrx Biosciences advances Ewing sarcoma research with ozekibart trial - Traders Union
Inhibrx Biosciences (INBX) Slips to $124.66 as Biotech Momentum CoolsDemand Zone - vinanet.vn
Inhibrx stock trades above $120 as latest deal reshapes the biotech story - AD HOC NEWS
INBX stock steadies near $120 as losses widen in latest quarter - AD HOC NEWS
Citizens reiterates Market Perform on Inhibrx Biosciences stock By Investing.com - Investing.com Canada
Inhibrx (INBX) Momentum: Records a 4.52% Increase to $103.63 in the Latest Reading; Next Test: the Session Ends Within the Reported Technical Boundaries on the DayIV Percentile - vinanet.vn
Stifel reiterates Buy on Inhibrx Biosciences stock, $325 target By Investing.com - Investing.com Canada
Inhibrx Biosciences (INBX) Earnings Put Its Valuation Back In Focus - Sahm
Inhibrx (INBX) Results at a Glance: The Bottom-Line Figure Trails Its Comparison in the Available Record; Trading Response: The Market Price Declines 2.92% in the Available RecordNegative Surprise Momentum - vinanet.vn
Western Standard LLC Takes $4.45 Million Position in Inhibrx Biosciences, Inc. $INBX - MarketBeat
Inhibrx (INBX) Q1 2026 Results: EPS Falls Short of Its Estimate in the Current Update; Market Move: The Stock Gains 7.25% at the CloseEarnings Stability Report - vinanet.vn
Stifel Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Maintains Target Price $325 - Moomoo
Inhibrx Biosciences (NASDAQ:INBX) Downgraded to Strong Sell Rating by Wall Street Zen - MarketBeat
INBX Q1 2026 Earnings: Wider-than-Expected Loss Reflects Elevated Pipeline InvestmentReturn On Capital - vinanet.vn
Should FDA Review of Ozekibart and INBRX-106 Data Milestones Require Action From Inhibrx (INBX) Investors? - simplywall.st
Trading the Move, Not the Narrative: (INBX) Edition - news.stocktradersdaily.com
Inhibrx Biosciences expands clinical evaluation of Ozekibart in new cancer study cohorts - Traders Union
Inhibrx Biosciences (INBX) Falls 8.9% to $88.37 as Downside Pressure BuildsUp Down Ratio - Vinanet
Inhibrx Biosciences (INBX) holders disclose 1.49M-share, 9.99% position - Stock Titan
Schonfeld Strategic Advisors (INBX) discloses 5.33% Inhibrx Biosciences stake in 13G filing - Stock Titan
Inhibrx (INBX): Viking Global group discloses 9.3% beneficial ownership stake - Stock Titan
Inhibrx Biosciences (INBX) Slides 8% to $89.22: Support at $84.76 Becomes Key TestNHNL Divergence - vinanet.vn
LifeSci Capital Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Maintains Target Price $230 - Moomoo
Buy Rating Reaffirmed on Inhibrx Ahead of Key INBRX-106 Phase 2 Readout; $230 Price Target Maintained - TipRanks
Inhibrx Biosciences (NASDAQ:INBX) Shares Gap Down After Earnings Miss - MarketBeat
Inhibrx Biosciences, Inc. (NASDAQ:INBX) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
INBX SWOT Analysis: Financial Challenges and Promising Pipeline Revealed in 10-Q Filing - GuruFocus
Inhibrx Biosciences (NASDAQ:INBX) Posts Quarterly Earnings Results, Misses Expectations By $0.06 EPS - MarketBeat
Form 8K Inhibrx Biosciences Inc For: 13 August By Investing.com - Investing.com Nigeria
Inhibrx Biosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Inhibrx Biosciences (INBX) deepens losses but reports pivotal ozekibart and INBRX-106 data - Stock Titan
Inhibrx Reports Second Quarter 2026 Financial Results - PR Newswire
Inhibrx Inc (INBX) Earnings, Actual EPS, EPS Estimates & Results - Stocktwits
Inhibrx Biosciences (INBX) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
Wall Street Zen Upgrades Inhibrx Biosciences (NASDAQ:INBX) to "Hold" - MarketBeat
Inhibrx Biosciences (INBX) to Announce Quarterly Earnings on Wednesday - MarketBeat
Inhibrx Biosciences (INBX) sees 5.9% ownership reported by Bank of America - Stock Titan
Swiss National Bank Invests $968,000 in Inhibrx Biosciences, Inc. $INBX - MarketBeat
Inhibrx Biosciences (NASDAQ:INBX) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Ongoing studies in rare cancer gain traction for Inhibrx Biosciences amid urgent patient needs - Traders Union
0.28%
4.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):